In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) was $27.64 for the day, down -1.36% from the previous closing price of $28.02. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 0.97 million shares were traded. ARWR stock price reached its highest trading level at $28.91 during the session, while it also had its lowest trading level at $27.22.
Ratios:
Our analysis of ARWR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.31 and its Current Ratio is at 8.31. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.82.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 02 ’24 when Oliver Tracie sold 9,394 shares for $25.28 per share. The transaction valued at 237,480 led to the insider holds 127,107 shares of the business.
Vakiener Victoria sold 1,799 shares of ARWR for $41,935 on May 02 ’24. The Director now owns 30,205 shares after completing the transaction at $23.31 per share. On Apr 01 ’24, another insider, Hamilton James C, who serves as the Chief Discovery/Trans Medicine of the company, sold 6,000 shares for $28.03 each. As a result, the insider received 168,180 and left with 204,851 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3432887808 and an Enterprise Value of 3323446272. For the stock, the TTM Price-to-Sale (P/S) ratio is 96.78 while its Price-to-Book (P/B) ratio in mrq is 7.09. Its current Enterprise Value per Revenue stands at 93.689 whereas that against EBITDA is -7.259.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $39.83, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 9.47%, while the 200-Day Moving Average is calculated to be 0.11%.
Shares Statistics:
ARWR traded an average of 1.07M shares per day over the past three months and 995710 shares per day over the past ten days. A total of 124.20M shares are outstanding, with a floating share count of 117.66M. Insiders hold about 5.26% of the company’s shares, while institutions hold 77.17% stake in the company. Shares short for ARWR as of 1719532800 were 8897038 with a Short Ratio of 8.28, compared to 1717113600 on 9022097. Therefore, it implies a Short% of Shares Outstanding of 8897038 and a Short% of Float of 8.4.
